206 related articles for article (PubMed ID: 21149494)
1. 18F-FPPRGD2 and 18F-FDG PET of response to Abraxane therapy.
Sun X; Yan Y; Liu S; Cao Q; Yang M; Neamati N; Shen B; Niu G; Chen X
J Nucl Med; 2011 Jan; 52(1):140-6. PubMed ID: 21149494
[TBL] [Abstract][Full Text] [Related]
2. (18)F-alfatide II and (18)F-FDG dual-tracer dynamic PET for parametric, early prediction of tumor response to therapy.
Guo J; Guo N; Lang L; Kiesewetter DO; Xie Q; Li Q; Eden HS; Niu G; Chen X
J Nucl Med; 2014 Jan; 55(1):154-60. PubMed ID: 24232871
[TBL] [Abstract][Full Text] [Related]
3. The feasibility of 18F-AlF-NOTA-PRGD2 PET/CT for monitoring early response of Endostar antiangiogenic therapy in human nasopharyngeal carcinoma xenograft model compared with 18F-FDG.
Cui Y; Liu H; Liang S; Zhang C; Cheng W; Hai W; Yin B; Wang D
Oncotarget; 2016 May; 7(19):27243-54. PubMed ID: 27029065
[TBL] [Abstract][Full Text] [Related]
4. PET imaging of early response to the tyrosine kinase inhibitor ZD4190.
Yang M; Gao H; Yan Y; Sun X; Chen K; Quan Q; Lang L; Kiesewetter D; Niu G; Chen X
Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1237-47. PubMed ID: 21360246
[TBL] [Abstract][Full Text] [Related]
5. DCE-MRI-Derived Parameters in Evaluating Abraxane-Induced Early Vascular Response and the Effectiveness of Its Synergistic Interaction with Cisplatin.
Sun X; Yang L; Yan X; Sun Y; Zhao D; Ji Y; Wang K; Chen X; Shen B
PLoS One; 2016; 11(9):e0162601. PubMed ID: 27632532
[TBL] [Abstract][Full Text] [Related]
6. [18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts.
Jensen MM; Erichsen KD; Johnbeck CB; Björkling F; Madsen J; Bzorek M; Jensen PB; Højgaard L; Sehested M; Kjær A
PLoS One; 2013; 8(1):e53410. PubMed ID: 23308217
[TBL] [Abstract][Full Text] [Related]
7. Biodistribution of the ¹⁸F-FPPRGD₂ PET radiopharmaceutical in cancer patients: an atlas of SUV measurements.
Minamimoto R; Jamali M; Barkhodari A; Mosci C; Mittra E; Shen B; Chin F; Gambhir SS; Iagaru A
Eur J Nucl Med Mol Imaging; 2015 Nov; 42(12):1850-8. PubMed ID: 26062933
[TBL] [Abstract][Full Text] [Related]
8. TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer.
Connolly RM; Leal JP; Goetz MP; Zhang Z; Zhou XC; Jacobs LK; Mhlanga J; O JH; Carpenter J; Storniolo AM; Watkins S; Fetting JH; Miller RS; Sideras K; Jeter SC; Walsh B; Powers P; Zorzi J; Boughey JC; Davidson NE; Carey LA; Wolff AC; Khouri N; Gabrielson E; Wahl RL; Stearns V
J Nucl Med; 2015 Jan; 56(1):31-7. PubMed ID: 25476537
[TBL] [Abstract][Full Text] [Related]
9. 18F-FDG small-animal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice.
McLarty K; Fasih A; Scollard DA; Done SJ; Vines DC; Green DE; Costantini DL; Reilly RM
J Nucl Med; 2009 Nov; 50(11):1848-56. PubMed ID: 19837760
[TBL] [Abstract][Full Text] [Related]
10. (18)F-FPPRGD2 PET/CT: pilot phase evaluation of breast cancer patients.
Iagaru A; Mosci C; Shen B; Chin FT; Mittra E; Telli ML; Gambhir SS
Radiology; 2014 Nov; 273(2):549-59. PubMed ID: 25033190
[TBL] [Abstract][Full Text] [Related]
11. Pilot prospective evaluation of (18)F-FPPRGD2 PET/CT in patients with cervical and ovarian cancer.
Minamimoto R; Karam A; Jamali M; Barkhodari A; Gambhir SS; Dorigo O; Iagaru A
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1047-55. PubMed ID: 26611425
[TBL] [Abstract][Full Text] [Related]
12. Stratification of 18F-labeled PET imaging agents for the assessment of antiangiogenic therapy responses in tumors.
Goggi JL; Bejot R; Moonshi SS; Bhakoo KK
J Nucl Med; 2013 Sep; 54(9):1630-6. PubMed ID: 23907757
[TBL] [Abstract][Full Text] [Related]
13. Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer.
Shah C; Miller TW; Wyatt SK; McKinley ET; Olivares MG; Sanchez V; Nolting DD; Buck JR; Zhao P; Ansari MS; Baldwin RM; Gore JC; Schiff R; Arteaga CL; Manning HC
Clin Cancer Res; 2009 Jul; 15(14):4712-21. PubMed ID: 19584166
[TBL] [Abstract][Full Text] [Related]
14. Therapy response monitoring of the early effects of a new BRAF inhibitor on melanoma xenograft in mice: evaluation of (18) F-FDG-PET and (18) F-FLT-PET.
Geven EJ; Evers S; Nayak TK; Bergström M; Su F; Gerrits D; Franssen GM; Boerman OC
Contrast Media Mol Imaging; 2015; 10(3):203-10. PubMed ID: 25204436
[TBL] [Abstract][Full Text] [Related]
15. Comparison of 18F-FES, 18F-FDG, and 18F-FMISO PET Imaging Probes for Early Prediction and Monitoring of Response to Endocrine Therapy in a Mouse Xenograft Model of ER-Positive Breast Cancer.
He S; Wang M; Yang Z; Zhang J; Zhang Y; Luo J; Zhang Y
PLoS One; 2016; 11(7):e0159916. PubMed ID: 27467716
[TBL] [Abstract][Full Text] [Related]
16. PET of HER2-positive pulmonary metastases with 18F-ZHER2:342 affibody in a murine model of breast cancer: comparison with 18F-FDG.
Kramer-Marek G; Bernardo M; Kiesewetter DO; Bagci U; Kuban M; Aras O; Zielinski R; Seidel J; Choyke P; Capala J
J Nucl Med; 2012 Jun; 53(6):939-46. PubMed ID: 22582046
[TBL] [Abstract][Full Text] [Related]
17. Quantitative Evaluation of Tumor Early Response to a Vascular-Disrupting Agent with Dynamic PET.
Guo N; Zhang F; Zhang X; Guo J; Lang L; Kiesewetter DO; Niu G; Li Q; Chen X
Mol Imaging Biol; 2015 Dec; 17(6):865-73. PubMed ID: 25896816
[TBL] [Abstract][Full Text] [Related]
18. Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG.
Beer AJ; Lorenzen S; Metz S; Herrmann K; Watzlowik P; Wester HJ; Peschel C; Lordick F; Schwaiger M
J Nucl Med; 2008 Jan; 49(1):22-9. PubMed ID: 18077538
[TBL] [Abstract][Full Text] [Related]
19. Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy.
Morrison MS; Ricketts SA; Barnett J; Cuthbertson A; Tessier J; Wedge SR
J Nucl Med; 2009 Jan; 50(1):116-22. PubMed ID: 19091899
[TBL] [Abstract][Full Text] [Related]
20. PET and macro- and microautoradiographic studies combined with immunohistochemistry for monitoring rat intestinal ulceration and healing processes.
Yamato M; Kataoka Y; Mizuma H; Wada Y; Watanabe Y
J Nucl Med; 2009 Feb; 50(2):266-73. PubMed ID: 19164236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
